750,000 Shares in Avanos Medical, Inc. $AVNS Acquired by Pentwater Capital Management LP

Pentwater Capital Management LP bought a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 750,000 shares of the company’s stock, valued at approximately $18,660,000. Pentwater Capital Management LP owned about 1.60% of Avanos Medical at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of AVNS. EverSource Wealth Advisors LLC lifted its stake in Avanos Medical by 132.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after buying an additional 1,423 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after purchasing an additional 2,307 shares during the period. Wexford Capital LP purchased a new stake in shares of Avanos Medical in the third quarter worth approximately $70,000. Longfellow Investment Management Co. LLC acquired a new stake in shares of Avanos Medical during the second quarter worth approximately $75,000. Finally, Tower Research Capital LLC TRC grew its position in Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after purchasing an additional 5,083 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on AVNS. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, July 20th. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Friday, June 5th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Avanos Medical has an average rating of “Reduce”.

Avanos Medical Price Performance

Shares of NYSE:AVNS opened at $24.99 on Thursday. Avanos Medical, Inc. has a 1-year low of $9.30 and a 1-year high of $25.49. The firm has a market capitalization of $1.17 billion, a PE ratio of -15.52 and a beta of 1.57. The business’s 50 day moving average is $24.96 and its 200-day moving average is $21.30. The company has a current ratio of 2.48, a quick ratio of 1.40 and a debt-to-equity ratio of 0.11.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.